Anlotinib: all 260 studies that test it

Page 1 of 3. Open to participants first (104), then studies with results posted, then the rest; newest registration first within each.

• MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingNCT07885709Phase 2
• A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)RecruitingNCT07863141Phase 2
• Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic CholangiocarcinomaNot yet recruitingNCT07846267Phase 2
• Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph NodesNot yet recruitingNCT07830355Phase 2
• A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLCRecruitingNCT07815223Phase 2
• The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07780578Phase 2
• Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain MetastasesNot yet recruitingNCT07745257Phase 2
• Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma ProtuberansNot yet recruitingNCT07646080Phase 2
• Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above TreatmentNot yet recruitingNCT07632209Phase 2
• Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)RecruitingNCT07627347Not applicable
• Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic CarcinomaNot yet recruitingNCT07616141Phase 2
• Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell CarcinomaNot yet recruitingNCT07602101Phase 2
• A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLCRecruitingNCT07562581Phase 2
• GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.Not yet recruitingNCT07540390Phase 3
• A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung CancerNot yet recruitingNCT07538271Phase 2
• Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung CancerNot yet recruitingNCT07538258Phase 2
• Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted TherapyNot yet recruitingNCT07537777Phase 2
• A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NECNot yet recruitingNCT07510594Phase 2
• Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Not yet recruitingNCT07501169Phase 2
• SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell CarcinomaNot yet recruitingNCT07470840Phase 2
• Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.RecruitingNCT07443397Phase 3
• Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy VolunteersNot yet recruitingNCT07438886Phase 1
• Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal CancerRecruitingNCT07398326Phase 2
• Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLCNot yet recruitingNCT07388875Phase 2
• Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line InductionNot yet recruitingNCT07376499Phase 2
• A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine TherapyRecruitingNCT07330544Phase 2
• Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.Not yet recruitingNCT07320963Phase 1/2
• A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.Not yet recruitingNCT07307443Phase 2
• Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLCNot yet recruitingNCT07294261Phase 2
• A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.Not yet recruitingNCT07205185Phase 2
• Anlotinib and Benmelstobart in DTCNot yet recruitingNCT07193186Phase 2
• Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung CancerNot yet recruitingNCT07172412Phase 2
• A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.Not yet recruitingNCT07156643Phase 2
• Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast CancerNot yet recruitingNCT07139470Phase 1/2
• Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in ChildrenNot yet recruitingNCT07137884Phase 2
• Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical StudyNot yet recruitingNCT07075250Phase 4
• Safety and Efficacy of Anlotinib in the Treatment of Recurrent CraniopharyngiomaRecruitingNCT06970145Phase 1/2
• Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line InductionNot yet recruitingNCT06951841Phase 4
• Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung CancerNot yet recruitingNCT06931145Phase 4
• Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic CholangiocarcinomaEnrolling by invitationNCT06901622Phase 2
• GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.RecruitingNCT06851247Phase 2
• Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic CarcinomaRecruitingNCT06838910Phase 2
• Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic NeoplasmsRecruitingNCT06767813Phase 2
• A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young AdultsRecruitingNCT06761417Phase 2
• Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingNCT06739395Phase 2
• Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCCNot yet recruitingNCT06699498Phase 2
• Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)Not yet recruitingNCT06681285Phase 2
• Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast CancerNot yet recruitingNCT06678230Phase 2
• Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line TreatmentNot yet recruitingNCT06662877Phase 2/3
• Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)Not yet recruitingNCT06621095Phase 2
• Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue SarcomaRecruitingNCT06506838Phase 4
• Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain MetastasesNot yet recruitingNCT06483672Phase 2
• Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingNCT06482086Phase 2
• A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer PatientsNot yet recruitingNCT06469879Phase 3
• Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLCNot yet recruitingNCT06456138Phase 1/2
• Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small CellNot yet recruitingNCT06441344Phase 3
• Anlotinib Combined With Benmelstobart for Advanced PheochromocytomaNot yet recruitingNCT06429397Phase 2
• Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06426797Phase 2
• A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to ImmunotherapyNot yet recruitingNCT06356675Phase 4
• A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06354530Phase 2/3
• To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung CancerRecruitingNCT06352008Phase 2
• Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast CancerRecruitingNCT06331169Phase 1
• Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy FailureNot yet recruitingNCT06327698Phase 2
• Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKIRecruitingNCT06277674Phase 2
• Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLCRecruitingNCT06258642Not applicable
• Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJANot yet recruitingNCT06222944Phase 2
• Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung CancerNot yet recruitingNCT06221462Phase 2
• Proteomic Guided First-line Precision Treatment of Renal Clear Cell CarcinomaRecruitingNCT06211790Phase 2
• The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical StudyRecruitingNCT06188650Not applicable
• Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung CancerRecruitingNCT06141226Phase 2
• Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic CancerRecruitingNCT06051851Phase 2
• Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICCNot yet recruitingNCT06033118Phase 1/2
• Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint InhibitorsNot yet recruitingNCT06031480Phase 2
• Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast CancerNot yet recruitingNCT06000033Phase 2
• A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLCRecruitingNCT05896059Phase 2
• Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal CancerRecruitingNCT05866510Phase 2
• Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal SarcomaEnrolling by invitationNCT05844813Phase 4
• Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)Not yet recruitingNCT05842018Phase 2
• Cadonilimab Plus Anlotinib for R/M/P Cervical CancerRecruitingNCT05817214Phase 2
• Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract CancerRecruitingNCT05812430Phase 2
• Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-MutationNot yet recruitingNCT05778149Phase 2
• PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid CancerRecruitingNCT05659186Phase 2
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
• Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial CancerNot yet recruitingNCT05550558Phase 2
• Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid TumorRecruitingNCT05490667Not applicable
• Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell CancerNot yet recruitingNCT05322499Phase 2
• Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung CancerNot yet recruitingNCT05306847Phase 2
• Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast CancerRecruitingNCT05296577Phase 2
• First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R MutationsRecruitingNCT05271916Phase 1/2
• Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLCNot yet recruitingNCT05218759Not applicable
• Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic CancerRecruitingNCT05218629Phase 2
• Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT05214222Phase 2
• First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural MesotheliomaRecruitingNCT05188859Phase 2
• The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast CancerRecruitingNCT05075512Phase 2
• TAS-102 and Anlotinib in ≥3 Lines mGCRecruitingNCT05029102Phase 2
• A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological CancerRecruitingNCT05028504Phase 2
• Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR MutationRecruitingNCT04936295Phase 2
• A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast CancerRecruitingNCT04914390Phase 2
• Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)Not yet recruitingNCT04846634Phase 2
• Anlotinib Plus Immune Checkpoint Inhibitors for Lung CancerRecruitingNCT04322617Phase 2/3

← Anlotinib overview